Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cullinan Therapeutics, Inc.CGEM · Entity 4766 | Director | June 10, 2024 | June 11, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cullinan Therapeutics, Inc.
Report date June 10, 2024 · Filed June 11, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 186,653 |
Reported balance
After 2024-06-10 transaction · row 1
1 source rowRow 1 · 2024-06-10 · Exercise / conversion · Acquired 18,450 · Balance 186,653 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.00 · Expires 2033-06-07 | Direct | 0 |
Reported balance
After 2024-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-10 · Exercise / conversion · Disposed 18,450 · Balance 0 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2024 Filed Jun 11, 2024 18:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,450 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0000950170-24-072095 · ownership.xml · derivative · entry 2 Ebeling Thomas · CIK 0001297759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,450 shares Expires 2033-06-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2024 Filed Jun 11, 2024 18:00 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionCommon Stock | 18,450 | $13.00 | $239,850.00 |
DisclosureSEC source: 0000950170-24-072095 · ownership.xml · nonDerivative · entry 1 Ebeling Thomas · CIK 0001297759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2024 Filed May 23, 2024 16:11 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,475 | $0.00 Strike: $12.73 | $0.00 |
DisclosureSEC source: 0000950170-24-063948 · ownership.xml · derivative · entry 4 Ebeling Thomas · CIK 0001297759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,475 shares Expires 2032-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2024 Filed May 23, 2024 16:11 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | Exercise / conversionStock Option (Right to Buy) · Derivative | 84,224 | $0.00 Strike: $4.30 | $0.00 |
DisclosureSEC source: 0000950170-24-063948 · ownership.xml · derivative · entry 3 Ebeling Thomas · CIK 0001297759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 84,224 shares Expires 2030-10-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares vested on August 16, 2018, and the remaining shares vested in 36 equal monthly installments thereafter. Read SEC document |
| May 23, 2024 Filed May 23, 2024 16:11 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 16,475 | $12.73 | $209,726.75 |
DisclosureSEC source: 0000950170-24-063948 · ownership.xml · nonDerivative · entry 2 Ebeling Thomas · CIK 0001297759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,203 Read SEC document |
| May 23, 2024 Filed May 23, 2024 16:11 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantCommon Stock | 84,224 | $4.30 | $362,163.20 |
DisclosureSEC source: 0000950170-24-063948 · ownership.xml · nonDerivative · entry 1 Ebeling Thomas · CIK 0001297759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,728 Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 17:58 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 18,450 | $0.00 Strike: $13.00 | $0.00 |
DisclosureSEC source: 0000950170-23-027540 · ownership.xml · derivative · entry 1 Ebeling Thomas · CIK 0001297759 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,450 Underlying: Common Stock · 18,450 shares Expires 2033-06-07 F1 · derivative.exercise_date: The option represents a right to purchase a total of 18,450 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 8, 2024 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 18:23 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 16,475 | $0.00 Strike: $12.73 | $0.00 |
DisclosureSEC source: 0000899243-22-023773 · doc4.xml · derivative · entry 1 Ebeling Thomas · CIK 0001297759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,475 Underlying: Common Stock · 16,475 shares Expires 2032-06-21 F1 · derivative.exercise_date: The option represents a right to purchase a total of 16,475 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 22, 2023 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
| September 16, 2021 Filed Mar 25, 2022 19:35 UTC | Cullinan Therapeutics, Inc. CGEM · Entity 4766 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0000899243-22-012380 · doc4.xml · derivative · entry 1 Ebeling Thomas · CIK 0001297759 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-09-15 F1 · derivative.exercise_date: The option represents a right to purchase a total of 7,800 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 25, 2022 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.